Literature DB >> 34654719

SGK2, 14-3-3, and HUWE1 Cooperate to Control the Localization, Stability, and Function of the Oncoprotein PTOV1.

Katie L Pennington1, Colten M McEwan1, James Woods1, Colin M Muir1, A G Pramoda Sahankumari1, Riley Eastmond1, Eranga R Balasooriya1, Christina M Egbert1, Sandeep Kaur2, Tyler Heaton3, Katherine K McCormack1, Stephen R Piccolo3, Manabu Kurokawa2, Joshua L Andersen4.   

Abstract

PTOV1 is an oncogenic protein, initially identified in prostate cancer, that promotes proliferation, cell motility, and invasiveness. However, the mechanisms that regulate PTOV1 remain unclear. Here, we identify 14-3-3 as a PTOV1 interactor and show that high levels of 14-3-3 expression, like PTOV1, correlate with prostate cancer progression. We discover an SGK2-mediated phosphorylation of PTOV1 at S36, which is required for 14-3-3 binding. Disruption of the PTOV1-14-3-3 interaction results in an accumulation of PTOV1 in the nucleus and a proteasome-dependent reduction in PTOV1 protein levels. We find that loss of 14-3-3 binding leads to an increase in PTOV1 binding to the E3 ubiquitin ligase HUWE1, which promotes proteasomal degradation of PTOV1. Conversely, our data suggest that 14-3-3 stabilizes PTOV1 protein by sequestering PTOV1 in the cytosol and inhibiting its interaction with HUWE1. Finally, our data suggest that stabilization of the 14-3-3-bound form of PTOV1 promotes PTOV1-mediated expression of cJun, which drives cell-cycle progression in cancer. Together, these data provide a mechanism to understand the regulation of the oncoprotein PTOV1. IMPLICATIONS: These findings identify a potentially targetable mechanism that regulates the oncoprotein PTOV1. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34654719      PMCID: PMC8816884          DOI: 10.1158/1541-7786.MCR-20-1076

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  59 in total

1.  PTOV1 is overexpressed in human high-grade malignant tumors.

Authors:  Sara Fernández; Jose L Mosquera; Lide Alaña; Alex Sanchez-Pla; Juan Morote; Santiago Ramón Y Cajal; Jaume Reventós; Inés de Torres; Rosanna Paciucci
Journal:  Virchows Arch       Date:  2010-12-23       Impact factor: 4.064

2.  Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase.

Authors:  T Kobayashi; M Deak; N Morrice; P Cohen
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

3.  Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.

Authors:  Fei Guo; Liu Feng; Ji-Long Hu; Mei-Ling Wang; Peng Luo; Xiao-Ming Zhong; An-Mei Deng
Journal:  Tumour Biol       Date:  2014-10-01

4.  ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

Authors:  Delin Chen; Ning Kon; Muyang Li; Wenzhu Zhang; Jun Qin; Wei Gu
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

5.  Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results.

Authors:  Mumtahena Rahman; Laurie K Jackson; W Evan Johnson; Dean Y Li; Andrea H Bild; Stephen R Piccolo
Journal:  Bioinformatics       Date:  2015-07-24       Impact factor: 6.937

Review 6.  Serum and glucocorticoid-regulated protein kinases: variations on a theme.

Authors:  Maude Tessier; James R Woodgett
Journal:  J Cell Biochem       Date:  2006-08-15       Impact factor: 4.429

7.  EDD mediates DNA damage-induced activation of CHK2.

Authors:  Michelle J Henderson; Marcia A Munoz; Darren N Saunders; Jennifer L Clancy; Amanda J Russell; Brandi Williams; Darryl Pappin; Kum Kum Khanna; Stephen P Jackson; Robert L Sutherland; Colin K W Watts
Journal:  J Biol Chem       Date:  2006-10-30       Impact factor: 5.157

8.  Bioinformatic and experimental survey of 14-3-3-binding sites.

Authors:  Catherine Johnson; Sandra Crowther; Margaret J Stafford; David G Campbell; Rachel Toth; Carol MacKintosh
Journal:  Biochem J       Date:  2010-03-15       Impact factor: 3.857

Review 9.  The role of prostate tumor overexpressed 1 in cancer progression.

Authors:  Verónica Cánovas; Matilde Lleonart; Juan Morote; Rosanna Paciucci
Journal:  Oncotarget       Date:  2017-02-14

10.  Prostate Tumor Overexpressed 1 (PTOV1) Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Poor Survival Outcomes.

Authors:  Qi Yang; Huanxin Lin; Shu Wu; Fangyong Lei; Xi Zhu; Libing Song; Minghuang Hong; Ling Guo
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.